Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
LMAT's Cash to Debt is ranked higher than
94% of the 307 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. LMAT: No Debt )
LMAT' s 10-Year Cash to Debt Range
Min: 0.1   Max: No Debt
Current: No Debt

Equity to Asset 0.84
LMAT's Equity to Asset is ranked higher than
91% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. LMAT: 0.84 )
LMAT' s 10-Year Equity to Asset Range
Min: 0.4   Max: 0.9
Current: 0.84

0.4
0.9
Interest Coverage 376.50
LMAT's Interest Coverage is ranked higher than
80% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. LMAT: 376.50 )
LMAT' s 10-Year Interest Coverage Range
Min: 2.32   Max: 9999.99
Current: 376.5

2.32
9999.99
F-Score: 6
Z-Score: 7.57
M-Score: -2.40
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 7.00
LMAT's Operating margin (%) is ranked higher than
71% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.05 vs. LMAT: 7.00 )
LMAT' s 10-Year Operating margin (%) Range
Min: -10.33   Max: 7.47
Current: 7

-10.33
7.47
Net-margin (%) 4.96
LMAT's Net-margin (%) is ranked higher than
71% of the 292 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.65 vs. LMAT: 4.96 )
LMAT' s 10-Year Net-margin (%) Range
Min: -7.08   Max: 10.73
Current: 4.96

-7.08
10.73
ROE (%) 5.66
LMAT's ROE (%) is ranked higher than
71% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. LMAT: 5.66 )
LMAT' s 10-Year ROE (%) Range
Min: -35.38   Max: 11.48
Current: 5.66

-35.38
11.48
ROA (%) 4.54
LMAT's ROA (%) is ranked higher than
75% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.19 vs. LMAT: 4.54 )
LMAT' s 10-Year ROA (%) Range
Min: -6.09   Max: 9.5
Current: 4.54

-6.09
9.5
ROC (Joel Greenblatt) (%) 19.99
LMAT's ROC (Joel Greenblatt) (%) is ranked higher than
76% of the 295 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.08 vs. LMAT: 19.99 )
LMAT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -35.74   Max: 29.28
Current: 19.99

-35.74
29.28
Revenue Growth (%) 5.50
LMAT's Revenue Growth (%) is ranked higher than
74% of the 274 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. LMAT: 5.50 )
LMAT' s 10-Year Revenue Growth (%) Range
Min: -4.9   Max: 21.4
Current: 5.5

-4.9
21.4
EBITDA Growth (%) 9.80
LMAT's EBITDA Growth (%) is ranked higher than
79% of the 237 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.90 vs. LMAT: 9.80 )
LMAT' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 27.9
Current: 9.8

0
27.9
EPS Growth (%) -18.50
LMAT's EPS Growth (%) is ranked higher than
58% of the 239 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.80 vs. LMAT: -18.50 )
LMAT' s 10-Year EPS Growth (%) Range
Min: -45   Max: 44.2
Current: -18.5

-45
44.2
» LMAT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

LMAT Guru Trades in

LMAT Guru Trades in

Q1 2014

LMAT Guru Trades in Q1 2014

Jim Simons 13,278 sh (New)
» More
Q2 2014

LMAT Guru Trades in Q2 2014

Jim Simons 20,262 sh (+52.6%)
» More
» Details

Insider Trades

Latest Guru Trades with LMAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 43.70
LMAT's P/E(ttm) is ranked higher than
61% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.90 vs. LMAT: 43.70 )
LMAT' s 10-Year P/E(ttm) Range
Min: 15.99   Max: 125
Current: 43.7

15.99
125
P/B 1.70
LMAT's P/B is ranked higher than
82% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.02 vs. LMAT: 1.70 )
LMAT' s 10-Year P/B Range
Min: 0.67   Max: 2.39
Current: 1.7

0.67
2.39
P/S 1.70
LMAT's P/S is ranked higher than
71% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. LMAT: 1.70 )
LMAT' s 10-Year P/S Range
Min: 0.63   Max: 2.98
Current: 1.7

0.63
2.98
PFCF 48.70
LMAT's PFCF is ranked higher than
63% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 65.30 vs. LMAT: 48.70 )
LMAT' s 10-Year PFCF Range
Min: 9.1   Max: 116.17
Current: 48.7

9.1
116.17
EV-to-EBIT 27.20
LMAT's EV-to-EBIT is ranked higher than
73% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.59 vs. LMAT: 27.20 )
LMAT' s 10-Year EV-to-EBIT Range
Min: 9.9   Max: 61.8
Current: 27.2

9.9
61.8
PEG 2.60
LMAT's PEG is ranked higher than
85% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMAT: 2.60 )
LMAT' s 10-Year PEG Range
Min: 2.11   Max: 3.72
Current: 2.6

2.11
3.72
Shiller P/E 38.40
LMAT's Shiller P/E is ranked higher than
74% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMAT: 38.40 )
LMAT' s 10-Year Shiller P/E Range
Min: 37.6   Max: 162.5
Current: 38.4

37.6
162.5
Current Ratio 5.88
LMAT's Current Ratio is ranked higher than
89% of the 223 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.00 vs. LMAT: 5.88 )
LMAT' s 10-Year Current Ratio Range
Min: 1.39   Max: 8.76
Current: 5.88

1.39
8.76
Quick Ratio 4.22
LMAT's Quick Ratio is ranked higher than
87% of the 223 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.09 vs. LMAT: 4.22 )
LMAT' s 10-Year Quick Ratio Range
Min: 0.73   Max: 7.26
Current: 4.22

0.73
7.26

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.80
LMAT's Dividend Yield is ranked higher than
65% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. LMAT: 1.80 )
LMAT' s 10-Year Dividend Yield Range
Min: 0.28   Max: 1.81
Current: 1.8

0.28
1.81
Dividend Payout 0.83
LMAT's Dividend Payout is ranked higher than
71% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMAT: 0.83 )
LMAT' s 10-Year Dividend Payout Range
Min: 0.25   Max: 1.25
Current: 0.83

0.25
1.25
Yield on cost (5-Year) 1.70
LMAT's Yield on cost (5-Year) is ranked higher than
61% of the 176 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. LMAT: 1.70 )
LMAT' s 10-Year Yield on cost (5-Year) Range
Min: 0.28   Max: 1.81
Current: 1.7

0.28
1.81
Share Buyback Rate 0.70
LMAT's Share Buyback Rate is ranked higher than
89% of the 236 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.20 vs. LMAT: 0.70 )
LMAT' s 10-Year Share Buyback Rate Range
Min: 0.7   Max: -22.6
Current: 0.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.90
LMAT's Price/Net Cash is ranked higher than
89% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMAT: 10.90 )
LMAT' s 10-Year Price/Net Cash Range
Min: 2.85   Max: 160.2
Current: 10.9

2.85
160.2
Price/Net Current Asset Value 4.40
LMAT's Price/Net Current Asset Value is ranked higher than
91% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMAT: 4.40 )
LMAT' s 10-Year Price/Net Current Asset Value Range
Min: 1.67   Max: 8.41
Current: 4.4

1.67
8.41
Price/Tangible Book 2.50
LMAT's Price/Tangible Book is ranked higher than
80% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.50 vs. LMAT: 2.50 )
LMAT' s 10-Year Price/Tangible Book Range
Min: 1.13   Max: 3.54
Current: 2.5

1.13
3.54
Price/DCF (Projected) 1.50
LMAT's Price/DCF (Projected) is ranked higher than
84% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.90 vs. LMAT: 1.50 )
LMAT' s 10-Year Price/DCF (Projected) Range
Min: 1.55   Max: 2.76
Current: 1.5

1.55
2.76
Price/Median PS Value 1.00
LMAT's Price/Median PS Value is ranked higher than
72% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.10 vs. LMAT: 1.00 )
LMAT' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 1.69
Current: 1

0.43
1.69
Price/Peter Lynch Fair Value 3.30
LMAT's Price/Peter Lynch Fair Value is ranked higher than
80% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. LMAT: 3.30 )
LMAT' s 10-Year Price/Peter Lynch Fair Value Range
Min: 2.27   Max: 3.73
Current: 3.3

2.27
3.73
Price/Graham Number 2.20
LMAT's Price/Graham Number is ranked higher than
79% of the 320 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.60 vs. LMAT: 2.20 )
LMAT' s 10-Year Price/Graham Number Range
Min: 1.19   Max: 3.03
Current: 2.2

1.19
3.03
Earnings Yield (Greenblatt) 3.70
LMAT's Earnings Yield (Greenblatt) is ranked higher than
55% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. LMAT: 3.70 )
LMAT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 10.1
Current: 3.7

1.6
10.1
Forward Rate of Return (Yacktman) 14.88
LMAT's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 259 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.15 vs. LMAT: 14.88 )
LMAT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -3.2   Max: 25.4
Current: 14.88

-3.2
25.4

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
LeMaitre Vascular Inc. was incorporated in Massachusetts on November 28, 1983, as Vascutech, Inc. On April 6, 2001, the Company changed its name to LeMaitre Vascular, Inc. It develops, manufactures, and markets vascular devices to address the needs of vascular surgeons. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart and are well known to vascular surgeons, including the Expandable LeMaitre Valvulotome, the Pruitt-Inahara Carotid Shunt, and VascuTape Radiopaque Tape. The Company has grown its business by using a three-pronged strategy: building a worldwide direct sales force, acquiring and developing complementary vascular devices, and developing and enhancing its in-house manufacturing competencies. Since 1998 it has completed ten acquisitions. It estimates that peripheral vascular disease affects more than 20 million people worldwide. It estimates that the annual worldwide market for all peripheral vascular devices is approximately $3 billion and that the annual worldwide market addressed by its 15 product lines approaches approximately $1 billion. The increasing incidence and diagnosis of peripheral vascular disease is driving the growth of the market for peripheral vascular devices. The Company's sales force was comprised of 61 field sales representatives in North America, the European Union, and Japan as of December 31, 2009. Clinical studies have identified several factors that increase the risk of peripheral vascular disease, including smoking, diabetes, obesity, high blood pressure, lack of exercise, coronary artery disease, high cholesterol, and being over the age of 65. The Company estimates that there are more than 2,000 board-certified vascular surgeons and several thousand general surgeons who perform vascular procedures in the United States, and that there are more than 3,000 vascular surgeons in Europe and Japan. Vascular surgeons perform both conventional vascular surgeries and endovascular procedures. Conventional vascular surgery involves opening the body, cutting vessels, and suturing. Endovascular procedures typically are minimally invasive, catheter-based procedures involving repairing vessels from within using real-time imaging technologies. Its goal is to be the global provider of medical devices to vascular surgeons. Endovascular products are used mainly by vascular surgeons in minimally invasive endovascular procedures, such as stent-grafting, angioplasty, stenting, and atherectomy. Vascular products are used mainly in open vascular surgery for the treatment of peripheral vascular disease. Its general surgery products are used mainly by general surgeons in non-vascular procedures. Its general surgery product is the Reddick Cholangiogram Catheter, which is used to inject dye into the cystic duct during a laparoscopic cholecystectomy. It conducts clinical studies in order to obtain regulatory approval and provide marketing
» More Articles for LMAT

Headlines

Articles On GuruFocus.com
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 10 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Aug 12 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 13 2010 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) Nov 13 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,500 Shares Jun 05 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,250 Shares May 28 2009 
LeMaitre Vascular Inc. (LMAT) CEO George W Lemaitre buys 1,000 Shares May 18 2009 
LeMaitre Vascular Inc. Reports Operating Results (10-Q) May 14 2009 


More From Other Websites
LEMAITRE VASCULAR INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD... Aug 19 2014
LeMaitre Vascular Acquires Omniflow II Manufacturer Xenotis Aug 19 2014
LEMAITRE VASCULAR INC Financials Aug 19 2014
The Benchmark Company Sees Xenotis Acquisition As Good For LeMaitre Vascular Aug 19 2014
LeMaitre Acquires Omniflow II Biologic Graft Aug 18 2014
10:16 am Lemaitre Vascular acquires Xenotis; total consideration was $7.7 million, consisting of... Aug 18 2014
LeMaitre Acquires Omniflow II Biologic Graft Aug 18 2014
LeMaitre Vascular to Present at the Canaccord Genuity 34th Annual Growth Conference on Thursday,... Aug 12 2014
LeMaitre Vascular to Present at the Canaccord Genuity 34th Annual Growth Conference on Thursday,... Aug 12 2014
LEMAITRE VASCULAR INC Files SEC form 10-Q, Quarterly Report Aug 07 2014
LeMaitre Q2 2014 Record Sales $18.2mm (+14%) ; Op. Profit $2.0mm (+37%) Jul 29 2014
LeMaitre Vascular Inc Earnings Call scheduled for 5:00 pm ET today Jul 29 2014
LEMAITRE VASCULAR INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 29 2014
LeMaitre Q2 2014 Record Sales $18.2mm (+14%) ; Op. Profit $2.0mm (+37%) Jul 29 2014
Q2 2014 LeMaitre Vascular Inc Earnings Release - After Market Close Jul 29 2014
LeMaitre Vascular Inc Stock Upgraded (LMAT) Jul 24 2014
LeMaitre Vascular Will Announce Second Quarter 2014 Earnings Results on July 29, 2014 Jul 21 2014
LeMaitre Vascular Will Announce Second Quarter 2014 Earnings Results on July 29, 2014 Jul 21 2014
LeMaitre Vascular (LMAT) Soars: Stock Adds 10.9% in Session Jun 25 2014
Coverage initiated on Lemaitre Vascular by Stifel Jun 24 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide